Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Apr 2018
At a glance
- Drugs Sofosbuvir/velpatasvir/voxilaprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms RESOLVE
- Sponsors Gilead Sciences
- 11 Apr 2018 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018.
- 11 Apr 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Dec 2018.
- 11 Apr 2018 Status changed from recruiting to active, no longer recruiting.